MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
5.95
-0.36
-5.71%
After Hours: 5.95 0 0.00% 17:38 06/05 EDT
OPEN
6.26
PREV CLOSE
6.31
HIGH
6.35
LOW
5.84
VOLUME
1.26M
TURNOVER
--
52 WEEK HIGH
8.00
52 WEEK LOW
0.5200
MARKET CAP
624.10M
P/E (TTM)
-5.1897
1D
5D
1M
3M
1Y
5Y
1D
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 4d ago
Hewlett Packard Posts Blowout Q2 Earnings, Joins Marvell Technology And Other Big Stocks Moving Higher In Tuesday's Session
Benzinga · 5d ago
Weekly Report: what happened at RLMD last week (0525-0529)?
Weekly Report · 6d ago
Relmada Therapeutics Increases Authorized Shares After Shareholder Vote
TipRanks · 05/28 22:58
Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval
Benzinga · 05/28 21:24
Relmada Therapeutics raises authorized common shares to 200 million from 150 million
PUBT · 05/28 21:01
RELMADA THERAPEUTICS - INCREASES AUTHORIZED COMMON STOCK TO 200 MLN SHARES FROM 150 MLN - SEC FILING
Reuters · 05/28 21:01
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.